HBV Treatment
EASL International Liver Congress Starts this Week in Amsterdam
- Details
- Category: HBV Treatment
- Published on Monday, 22 April 2013 00:00
- Written by Liz Highleyman
The 
48th Annual Meeting of the European Association for the Study of the Liver (EASL 2013) kicks off this Wednesday, April 24, at the Amsterdam RAI congress center. HIVandHepatitis.com will be on site to provide breaking news and analysis starting later this week.
CROI 2013: Dually Active Antiretroviral Therapy Protects Against Primary Hepatitis B Infection
- Details
- Category: HBV Treatment
- Published on Wednesday, 06 March 2013 00:00
- Written by Liz Highleyman
Use of antiretroviral therapy (ART) that includes drugs active against both hepatitis B virus (HBV) and HIV reduces the risk that HIV positive people will become infected with HBV -- in effect acting as HBV PrEP -- according to a study presented at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) this week in Atlanta.
Most Hepatitis B Patients Who Respond to Tenofovir Show Improved Liver Health at 5 Years
- Details
- Category: HBV Treatment
- Published on Thursday, 27 December 2012 00:00
- Written by Liz Highleyman
Treatment with tenofovir (Viread) remains safe and effective over 5 years, and people who achieve sustained viral load suppression experience improvement in liver histology, including regression of fibrosis and cirrhosis, according to study findings described in the December 7, 2012, advance online edition of The Lancet.
Antioxidant N-acetylcysteine Improves Survival of Transplanted Liver
- Details
- Category: HBV Treatment
- Published on Thursday, 28 February 2013 00:00
- Written by Liz Highleyman
N-acetylcysteine (NAC) administered during recovery of a liver from a deceased donor can help reduce damage during transplantation and increase survival of the liver graft in the recipient, according to a study published in the February 19, 2013, issue of Liver Transplantation.
AASLD 2012: Entecavir Shows Good Efficacy for Black and Hispanic Hepatitis B Patients
- Details
- Category: HBV Treatment
- Published on Tuesday, 18 December 2012 00:00
- Written by Liz Highleyman
The nucleoside analog entecavir (Baraclude) worked as well for previously untreated African-American and Hispanic/Latino hepatitis B patients as it did for the majority white and Asian study populations in prior clinical trials, according to a poster presented at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2012) last month in Boston.
More Articles...
- AASLD 2012: Adding Pegylated Interferon to Entecavir Improves HBV Treatment Response
- FDA: Do Not Mix Hepatitis B Drug Adefovir with Stribild HIV Combo Pill
- AASLD 2012: Nucleoside Analogs Reduce Hepatitis B Liver Cancer Risk, Cirrhosis Remains a Concern
- AASLD 2012: Tenofovir Safe and Effective for Long-term Hepatitis B Treatment with Little Bone Loss
Web Design and Development by